Financial reports
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
18 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Regulation FD Disclosure
22 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
8-K
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
19 Mar 24
8-K
Adicet Bio, Inc. Announces Proposed Public Offering
24 Jan 24
8-K
Regulation FD Disclosure
16 Jan 24
8-K
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
4 Jan 24
8-K
Departure of Directors or Certain Officers
13 Nov 23
8-K
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
8 Nov 23
8-K
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
9 Aug 23
8-K
Adicet Announces Appointment of Katie Peng to the Board of Directors
11 Jul 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 24
S-8
Registration of securities for employees
19 Mar 24
424B5
Prospectus supplement for primary offering
24 Jan 24
424B5
Prospectus supplement for primary offering
22 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8
Registration of securities for employees
9 Aug 23
S-8
Registration of securities for employees
15 Mar 23
424B5
Prospectus supplement for primary offering
8 Nov 22
S-3/A
Shelf registration (amended)
16 Mar 22
Proxies
DEFR14A
Revised proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
DEF 14A
Definitive proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
18 Mar 21
DEF 14A
Definitive proxy
18 Mar 21
Other
EFFECT
Notice of effectiveness
10 May 22
CORRESP
Correspondence with SEC
5 May 22
UPLOAD
Letter from SEC
16 Mar 22
EFFECT
Notice of effectiveness
24 May 21
CORRESP
Correspondence with SEC
19 May 21
UPLOAD
Letter from SEC
18 May 21
EFFECT
Notice of effectiveness
31 Mar 21
CORRESP
Correspondence with SEC
26 Mar 21
UPLOAD
Letter from SEC
18 Mar 21
EFFECT
Notice of effectiveness
21 Aug 20
Ownership
SC 13D/A
ORBIMED ADVISORS LLC
21 Mar 24
SC 13G
MILLENNIUM MANAGEMENT LLC
27 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G
MORGAN STANLEY
12 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24
SC 13D/A
Carlyle Group Inc.
7 Feb 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
5 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24